CO7240358A2 - Uso de 2-metileno-19-nor-(20s)-1a, 25- dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario - Google Patents

Uso de 2-metileno-19-nor-(20s)-1a, 25- dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario

Info

Publication number
CO7240358A2
CO7240358A2 CO15013584A CO15013584A CO7240358A2 CO 7240358 A2 CO7240358 A2 CO 7240358A2 CO 15013584 A CO15013584 A CO 15013584A CO 15013584 A CO15013584 A CO 15013584A CO 7240358 A2 CO7240358 A2 CO 7240358A2
Authority
CO
Colombia
Prior art keywords
dihydroxyvitamin
methylene
secondary hyperparathyroidism
treat secondary
treat
Prior art date
Application number
CO15013584A
Other languages
English (en)
Spanish (es)
Inventor
Hector F Deluca
Lori A Plum
Julia B Zella
Margaret Clagett-Dame
Original Assignee
Wisconsin Alumni Res Found
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=47997980&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO7240358(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Wisconsin Alumni Res Found filed Critical Wisconsin Alumni Res Found
Publication of CO7240358A2 publication Critical patent/CO7240358A2/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A61K31/593—9,10-Secocholestane derivatives, e.g. cholecalciferol, i.e. vitamin D3
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/59—Compounds containing 9, 10- seco- cyclopenta[a]hydrophenanthrene ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/18—Drugs for disorders of the endocrine system of the parathyroid hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Endocrinology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Rheumatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
CO15013584A 2012-06-29 2015-01-23 Uso de 2-metileno-19-nor-(20s)-1a, 25- dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario CO7240358A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201261666264P 2012-06-29 2012-06-29

Publications (1)

Publication Number Publication Date
CO7240358A2 true CO7240358A2 (es) 2015-04-17

Family

ID=47997980

Family Applications (1)

Application Number Title Priority Date Filing Date
CO15013584A CO7240358A2 (es) 2012-06-29 2015-01-23 Uso de 2-metileno-19-nor-(20s)-1a, 25- dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario

Country Status (19)

Country Link
US (4) US9205096B2 (enExample)
EP (1) EP2866811A1 (enExample)
JP (1) JP2015522015A (enExample)
KR (1) KR20150030673A (enExample)
CN (1) CN104394871A (enExample)
AU (1) AU2013281217B2 (enExample)
BR (1) BR112014032847A2 (enExample)
CA (1) CA2877680C (enExample)
CL (1) CL2014003565A1 (enExample)
CO (1) CO7240358A2 (enExample)
HK (1) HK1206600A1 (enExample)
IL (1) IL236184A0 (enExample)
MX (1) MX2015000076A (enExample)
MY (1) MY172886A (enExample)
NZ (1) NZ703347A (enExample)
RU (1) RU2666995C2 (enExample)
SG (1) SG11201408731WA (enExample)
WO (1) WO2014003849A1 (enExample)
ZA (1) ZA201500119B (enExample)

Families Citing this family (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20150030673A (ko) * 2012-06-29 2015-03-20 위스콘신 얼럼나이 리서어치 화운데이션 속발성 부갑상선기능항진증을 치료하기 위한 2-메틸렌-19-노르-(20S)-1α,25-디히드록시비타민 D₃의 용도
KR102341026B1 (ko) * 2013-09-27 2021-12-21 코덱시스, 인코포레이티드 구조에 기반한 예측 모델링
SG11201601695WA (en) 2013-09-27 2016-04-28 Codexis Inc Automated screening of enzyme variants
CN103533522A (zh) * 2013-10-25 2014-01-22 从兴技术有限公司 短信稽核的方法及系统
US10220047B2 (en) * 2014-08-07 2019-03-05 Opko Ireland Global Holdings, Ltd. Adjunctive therapy with 25-hydroxyvitamin D and articles therefor
US10369161B2 (en) 2014-12-30 2019-08-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-NOR-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat primary hyperparathyroidism
US9539264B2 (en) * 2014-12-30 2017-01-10 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-(20S)-1-alpha,25-dihydroxyvitamin D3 to treat secondary hyperparathyroidism in patients previously treated with calcimimetics
WO2018044468A1 (en) 2016-08-30 2018-03-08 Wisconsin Alumni Research Foundation COMBINATION OF LOW DOSE 2-METHYLENE-19-NOR-(20S)-1α, 25-DIHYDROXYVITAMIN D3 AND CALCIMIMETICS TO TREAT SECONDARY HYPERPARATHYROIDISM

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040043971A1 (en) 1995-04-03 2004-03-04 Bone Care International, Inc. Method of treating and preventing hyperparathyroidism with active vitamin D analogs
US6306844B1 (en) 1997-03-17 2001-10-23 Wisconsin Alumni Research Foundation Use of 2α-methyl-19-nor-20(S)-1α, 25-dihydroxyvitamin D3 to increase bone strength
US5843928A (en) 1997-03-17 1998-12-01 Wisconsin Alumni Research Foundation 2-alkylidene-19-nor-vitamin D compounds
US6136799A (en) 1998-04-08 2000-10-24 Abbott Laboratories Cosolvent formulations
US6673782B2 (en) 1999-04-29 2004-01-06 Wisconsin Alumni Research Foundation Treatment of systemic lupus erythematosis
NZ521923A (en) 2000-03-27 2004-11-26 Wisconsin Alumni Res Found Vitamin D compounds used to stabilize kidney transplants
CA2416194C (en) * 2000-07-14 2009-10-06 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(s)-1.alpha.,25-dihydroxyvitamin d3 to increase bone strength
US20080249068A1 (en) 2002-09-05 2008-10-09 Deluca Hector F Method of Extending the Dose Range of Vitamin D Compounds
US20050124591A1 (en) 2003-07-29 2005-06-09 Jin Tian Use of vitamin Ds to treat kidney disease
US20060171983A1 (en) 2003-07-30 2006-08-03 Jin Tian Use of Vitamin D receptor activators or Vitamin D analogs to treat cardiovascular disease
JP2007505882A (ja) * 2003-09-19 2007-03-15 ファイザー・プロダクツ・インク 脆弱、筋損傷又はサルコペニアの治療のための２−アルキリデン−１９−ノル−ビタミンｄ誘導体
US7704980B2 (en) 2003-10-08 2010-04-27 Wisconsin Alumni Research Foundation Treatment of inflammatory bowel disease with 2-methylene-19-nor-vitamin D compounds
US7214671B2 (en) 2004-02-19 2007-05-08 Wisconsin Alumni Research Foundation Use of 2-methylene-19-nor-20(S)-1α,25-dihydroxyvitamin D3 for the prophylaxis of bone diseases
US7563783B2 (en) 2005-02-11 2009-07-21 Wisconsin Alumni Research Foundation 2-methylene-19-nor-(20S-24S)-1α,25-dihydroxyvitamin-D2
US7528122B2 (en) * 2006-02-02 2009-05-05 Wisconsin Alumni Research Foundation Vitamin D analog—NEL, methods and uses thereof
US20110034426A1 (en) * 2009-08-03 2011-02-10 Wisconsin Alumni Research Foundation Method of Preventing Renal Disease and Treating Symptoms Thereof
CA2794006C (en) 2010-03-23 2017-11-28 Wisconsin Alumni Research Foundation (20s)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-dihydroxyvitamin d3 and (20r)-2-methylene-19-nor-22-dimethyl-1.alpha.,25-hydroxyvitamin d3
KR20150030673A (ko) * 2012-06-29 2015-03-20 위스콘신 얼럼나이 리서어치 화운데이션 속발성 부갑상선기능항진증을 치료하기 위한 2-메틸렌-19-노르-(20S)-1α,25-디히드록시비타민 D₃의 용도

Also Published As

Publication number Publication date
MY172886A (en) 2019-12-13
MX2015000076A (es) 2015-04-10
WO2014003849A1 (en) 2014-01-03
AU2013281217A1 (en) 2015-01-22
CA2877680C (en) 2017-08-29
US9205096B2 (en) 2015-12-08
ZA201500119B (en) 2017-11-29
RU2666995C2 (ru) 2018-09-13
CN104394871A (zh) 2015-03-04
RU2015102831A (ru) 2016-08-20
US9034853B2 (en) 2015-05-19
KR20150030673A (ko) 2015-03-20
EP2866811A1 (en) 2015-05-06
US20160136184A1 (en) 2016-05-19
JP2015522015A (ja) 2015-08-03
BR112014032847A2 (pt) 2017-06-27
CA2877680A1 (en) 2014-01-03
US20140005152A1 (en) 2014-01-02
SG11201408731WA (en) 2015-01-29
IL236184A0 (en) 2015-01-29
US20140187522A1 (en) 2014-07-03
CL2014003565A1 (es) 2015-08-28
AU2013281217B2 (en) 2017-03-02
US20170252360A1 (en) 2017-09-07
NZ703347A (en) 2016-05-27
HK1206600A1 (en) 2016-01-15
US10046000B2 (en) 2018-08-14
US9717744B2 (en) 2017-08-01

Similar Documents

Publication Publication Date Title
CO7240358A2 (es) Uso de 2-metileno-19-nor-(20s)-1a, 25- dihidroxivitamina d3 para tratar el hiperparatiroidismo secundario
MX2022014331A (es) Metodos y composiciones para el tratamiento de trastornos epilepticos.
UY37036A (es) Compuestos inhibidores de la quinasa de unión a tank
MX2019008148A (es) Uso de peptidos glp-1 de accion prolongada.
UY36445A (es) Compuestos moduladores de fxr (nr1h4 que contiene grupos hidroxi)
CR20160069A (es) Compuestos terapéuticamente activos y sus métodos de uso
CR20160272A (es) REGULADORES DE Nrf2
UY36452A (es) Novedosos compuestos moduladores de fxr (nr1h4)
AR097481A1 (es) Cocristales energéticos para el tratamiento de una formación subterránea
CL2014003572A1 (es) Compuestos derivados de aril-sultamo o una sal del mismo, como moduladores de la funcion del receptor de orfano rorc; composicion que los contiene; y su uso para el tratamiento o la profilaxis de la artritis.
DOP2015000274A (es) Compuestos químicos
NI201400125A (es) Antagonistas de st2l y métodos de uso
CL2014002915A1 (es) Compuestos derivados de imidazotiadiazol e imidazopirazina, como inhibidores del receptor activado de proteasa 4 (par4); composicion farmaceutica que los comprende; y su uso para inhibir o prevenir la agregacion plaquetaria y por lo tanto utiles en el tratamiento de un trastorno tromboembolico o para la profilaxis primaria o secundaria de un trastorno tromboembolico.
MX2016010237A (es) Metodos de tratamiento de enfermedad de alzheimer.
CL2015000976A1 (es) Compuestos de 2-fenil-5-heterociclil-tetrahidro-2h-piran-3-amina para uso en el tratamiento de diabetes y sus trastornos asociados.
CR20170077A (es) Derivados de heterociclilo opcionalmente condensados de pirimidina útiles para el tratamiento de enfermedades inflamatorias, metabólicas, oncológicas y autoinmunitarias
CL2018002023A1 (es) Uso de moduladores de receptores de gabaa para el tratamiento de picor.
CL2018002645A1 (es) Sulfonamidas sustituidas para controlar plagas animales
UY37472A (es) Sulfonilamidas sustituidas para combatir parásitos animales
AR089320A1 (es) Cepa de lactobacillus mucosae
SV2017005368A (es) [1,2,4] triazolo [4,3-b] piridazinas para su uso en el tratamiento de enfermedades proliferativas
MX392703B (es) Uso de anticuerpos anti-il-23a para tratar psoriasis pustulosa generalizada.
UY34461A (es) Compuestos de hidrocarburos aromáticos policíclic os que contienen un átomo de s o un grupo s(=o)2 en su estructura básica
BR112018067602A2 (pt) ambrisentan para uso no tratamento de insuficiência renal aguda
CO2017003067A2 (es) Compuestos de dipeptidil-cetoamida